Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Allergan, Merck sales and marketing update

    Allergan plc (NYSE:AGN), Dublin, Ireland Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Neurology Allergan launched 2.5 mg Saphris asenapine black cherry-flavored sublingual tablets in the U.S. to treat manic …

    Published on 8/24/2015
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Diagnostic Biocept launched its blood-based BRAF mutations assay to help determine which treatments will benefit melanoma patients. The company could not provide …

    Published on 8/24/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer Germanys Institute for Quality and Efficiency in Health Care (IQWiG) said in a dossier assessment Gilotrif/Giotrif afatinib from Boehringer had a major …

    Published on 8/24/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Diagnostic Eisais Eidia Co. Ltd. subsidiary launched Stacia Cleia Pivka-II in Japan with an automated immunoanalyzer from LSI Medience Co. Ltd. (Tokyo, Japan) to …

    Published on 8/24/2015
  • Epigenomics, BioChain Institute sales and marketing update

    Epigenomics AG (Xetra:ECX), Berlin, Germany BioChain Institute Inc., Newark, Calif. Business: Diagnostic Epigenomics said the Chinese Guideline on Screening, Endoscopic Diagnosis and Treatment of Early Colorectal Cancer…

    Published on 8/24/2015
  • Genomic Health sales and marketing update

    Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Business: Diagnostic Genomic Health said Medicare administrative contractor Palmetto GBA LLC (Columbia, S.C.) issued a local coverage determination (LCD) that …

    Published on 8/24/2015
  • GlaxoSmithKline sales and marketing update

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Infectious GlaxoSmithKline began shipping doses of Fluarix Quadrivalent for the 2015-16 flu season to U.S. pharmacies and healthcare providers. Fluarix is …

    Published on 8/24/2015
  • Mylan sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Neurology, Generics Mylan launched 5 and 10 mg memantine tablets in the U.S. to treat moderate to severe dementia from Alzheimers disease (AD). Memantine is a generic …

    Published on 8/24/2015
  • Newron sales and marketing update

    Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Business: Neurology The German Institute for Quality and Efficiency in Health Care (IQWiG) said data from Newron supporting Xadago safinamide were incomplete and …

    Published on 8/24/2015
  • Teva sales and marketing update

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Neurology, Generics Teva launched 6.25 and 12.5 mg almotriptan tablets in the U.S. to treat migraines. The oral selective serotonin (5-HT1D)…

    Published on 8/24/2015
  • Biocept sales and marketing update

    Biocept Inc. (NASDAQ:BIOC), San Diego, Calif. Business: Pharmacogenetics Biocept launched a blood-based FGFR1 amplification test to identify fibroblast growth factor (FGF) receptor 1 (FGFR1; CD331) amplification in …

    Published on 8/17/2015
  • Boehringer Ingelheim sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Pulmonary Boehringer launched Stiolto Respimat tiotropium/olodaterol in the U.S. to treat chronic obstructive pulmonary disease (COPD). The wholesale acquisition …

    Published on 8/17/2015
  • Cerus, SunCoast Blood Bank Inc. sales and marketing update

    Cerus Corp. (NASDAQ:CERS), Concord, Calif. SunCoast Blood Bank Inc., Sarasota, Fla. Business: Hematology SunCoast implemented Cerus Intercept Blood System for platelets at bloodbanks in southwest Florida. Cerus said it …

    Published on 8/17/2015
  • Daiichi Sankyo sales and marketing update

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cardiovascular The U.K.s NICE issued a final appraisal determination (FAD) for Lixiana edoxaban from Daiichi to treat and prevent deep vein thrombosis (DVT) …

    Published on 8/17/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer, Neurology Eisai launched Lenvima lenvatinib in Germany, Austria and the Nordic countries to treat patients with radioactive iodine refractory differentiated …

    Published on 8/17/2015
  • Great Basin sales and marketing update

    Great Basin Corp. (NASDAQ:GBSN), Salt Lake City, Utah Business: Diagnostic Great Basin launched its Portrait GBS Assay in U.S. hospitals and laboratories and in more than 32 countries accepting the CE-IVD Mark to detect…

    Published on 8/17/2015
  • Iroko sales and marketing update

    Iroko Pharmaceuticals LLC, Philadelphia, Pa. Business: Neurology Iroko launched Tivorbex indomethacin in the U.S. to treat mild to moderate acute pain in adults. The lower dose submicron formulation of the NSAID …

    Published on 8/17/2015
  • Merck KGaA sales and marketing update

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Diagnostic Mercks Merck Serono S.A. unit launched Early Embryo Viability Assessment (Eeva) test in undisclosed European countries to improve in vitro fertilization …

    Published on 8/17/2015
  • Multiplicom sales and marketing update

    Multiplicom N.V., Niel, Belgium Business: Diagnostic Multiplicom launched the CLL MASTR Plus Kit worldwide for research use only to improve diagnosis of patients with chronic lymphocytic leukemia (CLL). The mutation kit…

    Published on 8/17/2015
  • Mylan sales and marketing update

    Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Business: Cancer, Generics Mylan launched bexarotene 75 mg capsules in the U.S. to treat cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to …

    Published on 8/17/2015
  • Roche sales and marketing update

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cardiovascular Roche launched its CARDIAC point-of-care Troponin T test for the cobas h 232 system in countries accepting the CE Mark. The test identifies …

    Published on 8/17/2015
  • SkylineDx sales and marketing update

    SkylineDx B.V., Rotterdam, the Netherlands Business: Diagnostic SkylineDx launched the MMprofiler test in Europe to predict prognosis of patients with multiple myeloma (MM). The micro-array based gene expression …

    Published on 8/17/2015
  • Symplmed sales and marketing update

    Symplmed Pharmaceuticals LLC, Cincinnati, Ohio Business: Cardiovascular Symplmed launched Prestalia perindopril/amlodipine tablets in the U.S. to treat hypertension. The initial recommended dose is 2.5 amlodipine/3.5 …

    Published on 8/17/2015
  • AbbVie, Bristol-Myers, Merck, Pfizer, Roche, UCB sales and marketing update

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, …

    Published on 8/10/2015
  • Biodesix, Aetna sales and marketing update

    Biodesix Inc., Boulder, Colo. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Cancer Aetna issued a positive coverage decision for Biodesixs blood-based proteomic test VeriStrat for advanced non-small cell lung cancer…

    Published on 8/10/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993